


CONTACT INFORMATION: **Elana Holzman** Tel +972-3-926-7554, E-mail: elana.holzman@teva.co.il **Kevin Mannix** Tel (215) 591-8912, E-mail: kevin.mannix@tevausa.com

Company Overview

Teva Pharmaceutical Industries Ltd., is among the top 15 pharmaceutical companies in the world and the leader in generic pharmaceuticals, specializing in development, production and marketing of a wide range of generic, innovative and branded pharmaceuticals, biogenerics and active pharmaceutical ingredients. Teva currently operates in over 60 countries with some 40,000 employees worldwide. Its innovative R&D efforts focus on therapies for the central nervous system (with emphasis

on multiple sclerosis), autoimmune diseases and oncology. Teva differentiates itself by balancing its portfolio with generic, innovative and branded products, vertically integrating its pharmaceutical and API activities, combining local customer responsiveness with a "global edge", and by its global footprint. Teva's success lies in the leadership of its management, the skills and devotion of its people, the quality of its offerings and its focus on customers and patients.

Net Sales (U.S. \$ in Millions)




Market Data (As of February 7, 2011)

| | |
|-----------------------|-------------------|
| Stock Symbol | TEVA |
| Closing Price | \$54.98 |
| 52 Week Range | \$46.99 - \$64.95 |
| Market Capitalization | \$49.4 billion |
| #12 in NASDAQ-100 | |


NASDAQ-100

NBI
NASDAQ
NASDAQ BIOTECHNOLOGY™ **INDEX**


Net Income^(1,2) (U.S. \$ in Millions)




Stock Chart (As of February 7, 2011)



Earning Per Share^(1,2) (U.S. \$)



R&D Expenses (net) (U.S. \$ in Millions)



(1) Reflects non-GAAP results. (2) Reflects retroactive adjustment following the adoption of APB14-1.

Recent Events

January 26, 2011 - Teva announced the acquisition of Corporacion Infarmasa, a top ten pharmaceutical company in Peru. Infarmasa manufactures and commercializes branded and unbranded generic drugs, primarily corticosteroids, antihistamines, analgesics and antibiotics, with over 600 registered products, of which over 500 are currently marketed. The combination of Corporacion Medco (Teva's existing operation in Peru) and Infarmasa is one of the top two pharmaceutical companies in the country. The Peruvian pharmaceutical market grew at a CAGR of 12% from 2005 to 2010 and is expected to reach \$1.8 billion in 2015.

January 26, 2011 - Teva and APP announced the commercial launch of the generic version of Gemzar® in the U.S. Annual sales of Eli Lilly's Gemzar® were approximately \$785 million in the U.S. in 2010. Under the agreement, APP will manufacture generic Gemzar® and will receive a license from Teva to market the product within Teva's 180-day exclusivity. In return, Teva will receive a royalty during the manufacturing term.

January 25, 2011 - Teva received correspondence from the FDA regarding the Company's ANDA for generic Lovenox® injection. The receipt of this action letter, called a Minor Deficiency letter, indicates that the FDA has completed its review of the ANDA. Prior to potential final product approval, the Office of Generic Drugs requires responses to a short list of questions, which Teva intends to respond to in the near future.

January 5, 2011 - Teva completed the acquisition Theramex from Merck KGaA. Theramex offers a wide variety of women's health products sold in 50 countries worldwide and had revenues of approximately €100 million in 2009. A significant portion of its revenues are derived from direct sales in France and Italy. The company's pipeline includes a new oral contraceptive based on natural

estrogens, NOMAC/E2, which has successfully completed phase III studies and submitted for approval in Europe.



December 23, 2010 - Teva received a complete response letter from the FDA for its sNDA for a lower-volume (0.5mL) injection of glatiramer acetate. The letter stated that the FDA could not approve the application as submitted. The FDA noted that the 0.5mL formulation contained the same active ingredient as the currently marketed Copaxone®, but that because the mechanism of action of Copaxone® is not fully understood, even a formulation change could impact clinical outcomes. This response supports Teva's belief that even slight changes to a glatiramoid like Copaxone® can significantly and unpredictably influence the efficacy, toxicity and immunogenicity profile of the compound.

December 9, 2010 - Teva and Active Biotech announced initial results from the two-year Phase III ALLEGRO study, which demonstrated that RRMS patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale, were also achieved. Laquinimod was safe and well-tolerated.

November 4, 2010 - Teva presented its respiratory growth strategy. Teva's expertise in the respiratory marketplace, combined with the strength of its unique product pipeline, is expected to contribute approximately \$2.4 billion to the Company's overall 2015 targets of \$31 billion. Teva intends to file 10 products, six of which are new brands, for approval in the U.S. and Europe by 2015, targeting approximately \$25 billion in brand value, including new combination products.


Sales by Region

Q4/10: \$4.42 billion




(1) Includes EU member states, Switzerland & Norway
(2) Includes Mexico

U.S. Generic Pipeline (As of February 5, 2011)



COPAXONE® Global In-Market Sales (U.S. \$ in Millions)



Branded Pharmaceuticals - Pipeline

| Marketed products | End Phase III 2011-2012 | End Phase III 2012-2015 |
|--|--|--|
| <ul style="list-style-type: none"> Women's Health Biologics Copaxone® - Multiple Sclerosis & CIS Azilect® - Parkinson's PolyHeal™ - Chronic Wounds QVAR® - Inhaled Steroid ProAir™ - Inhaled short acting beta-mimetic Easi-Breathe products Asthma & COPD Seasonique® / LoSeasonique® - Extended Regimen Contraception Plan B® One-Step Emergency Contraception ParaGard® - Intrauterine Contraception Enjuvia™ - Hormone Therapy TEV-TROPIN® - Growth Hormone Deficiency TevaGrastim® / Ratiograstim® / Biograsatim™ - Hematology Eporatio®/Biopoin™ - Hematology | <ul style="list-style-type: none"> Laquinimod - Oral Multiple Sclerosis (Phase III) StemEx® - Hemato-oncological (Phase III) NexoBrid® - Burns (Phase III) Azilect® MSA (Phase II) BDP HFA Nasal (QNAZE™) - Rhinitis (Phase III) BFC Spiromax - Asthma/COPD (Phase III) Albuterol Spiromax - Asthma/COPD (Phase III) FP HFA MDI - Asthma (Phase III) FCS HFA MDI - Asthma (Phase III) NOMAC/E2 - Oral Contraception (Phase III) DR-103 - Contraception (Phase III) Oxybutynin Vaginal Ring Overactive Bladder (Phase III) Progesterone Vaginal Ring Infertility (Phase III) DR-102 - Contraception (Phase III) Follitropin alfa Gynecology / Andrology (Phase III) Glyo-PEG-G-CSF - Hematology (Phase III) Neugarin™ - Hematology (Phase III) | <ul style="list-style-type: none"> TV-1101 (OGX-011) Prostate Cancer 1st line (Phase III) TV-1101 (OGX-011) Prostate Cancer 2nd line TV-1101 (OGX-011) Lung Cancer (Phase III) DiaPep-277 - Type I Diabetes (Phase III) Laquinimod - Crohn's disease (Phase II) CT-011 - Hemato - Oncological (Phase II) CT-011 - Solid Tumor Oncology (Phase II) Laquinimod - Lupus (Phase II) MultiGene Angio Critical Limb Ischemia (Phase II) FP Spiromax - Asthma (Phase III) FSC Spiromax - Asthma (Phase III) Vaginal Ring (undisclosed) Menopause product (undisclosed) Rituximab (Phase II) 2 Biosimilars projects (undisclosed) |

Selected U.S. Generic Approvals (November 2010 - January 2011)

| Product | | Approval/ Launch Date | Branded Product | | Indication |
|------------------------------|-----------|--------------------------|-----------------|--------------------------------------|---|
| | | | Name | Market size (U.S. \$ in Millions) | |
| Atomoxetine ⁽²⁾ | Capsules | 01/10/10 | Strattera® | 526 | Treatment of ADHD |
| Pramipexole ⁽¹⁾ | Tablets | 08/10/10 | Mirapex® | 508 | Treatment of Parkinson's Disease |
| Lansoprazole ⁽¹⁾ | DR ODT | 15/10/10 | Prevacid® | 371 | Gastric-acid pump inhibitor |
| Linezolid ⁽³⁾ | Tablets | 29/10/10 | Zyvox® | 404 | Antibiotic |
| Donepezil HCl ⁽¹⁾ | ODT | 26/11/10 | Aricept® | 11 | Treatment of alzheimer's dementia |
| Dutasteride ⁽²⁾ | Capsules | 25/01/11 | Avodart® | 586 | Treatment of signs & symptoms of benign prostatic hyperplasia |
| Gemcitabine ⁽²⁾ | Injection | 21/01/11 | Gemzar® | 814 | Chemotherapy (ovarian, breast, pancreatic and non-small cell lung cancer) |

(1) Launched (2) Exclusivity (180 days) (3) Tentative approval